Evidence map›Paper›PMID 40881551›Full record

ArticleCureus2025

Multiple Organ Failure Due to Leukostasis Caused by Rapidly Progressive Hyperleukocytosis: A Case Report.

Takanori Ohno, Tasuku Takahashi, Kazunori Murai, Hiroshi Nashiki

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Takanori OhnoEmergency Medicine, Iwate Prefectural Central Hospital, Morioka, JPN.
Tasuku TakahashiNephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, JPN.
Kazunori MuraiHematology, Iwate Prefectural Central Hospital, Morioka, JPN.
Hiroshi NashikiEmergency Medicine, National Health Insurance Hanamakishi Ishidoriya Medical Center, Morioka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is common in older adults and progresses to acute myeloid leukemia (AML) with a poor prognosis. Here, we present the case of a 71-year-old man undergoing treatment for MDS who was brought to the hospital for emergency care after suddenly becoming disoriented while on a trip. Laboratory results revealed a markedly increased white blood cell count (468,480/μL) with a predominance of blast cells (89%), and he was diagnosed with hyperleukocytosis (HL) and leukostasis associated with acute conversion to AML (probably M4). After surviving two cardiac arrests, the patient was deemed not strong enough to survive another cardiopulmonary arrest. A decision was made to withdraw from invasive treatment in the acute phase, and the patient died within eight hours of arrival at the hospital. It is challenging to determine whether the cause of vascular occlusion is a thrombus or a blast cell. Generally, when leukostasis is associated with HL and monocyte proliferation, occlusion by blast cells is the most common cause. Leukostasis is caused by the adhesion of intravascular blast cells and increased blood viscosity and is fatal, particularly in the respiratory and central nervous systems. Treatments include hydroxyurea/low-dose chemotherapy and leukapheresis; however, evidence of their ability to improve early mortality is lacking. In older patients, family opinion plays a vital role in treatment decisions, and collaboration with hematologists is essential.

Indexed as

acute myeloid leukemia (aml)blast cellshematologist collaborationhydroxyureahyperleukocytosis (hl)leukapheresisleukostasismonocyte proliferationmyelodysplastic syndrome (mds)vascular occlusion

Identifiers

PMID40881551
PMCPMC12381543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.